Arena down 3% after CHMP issues host of recommendations

theflyonthewall.com

Arena Pharmaceuticals shares are down 3%, or 34c, to $10.11 in pre-market trading after the European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, announced a host of opinions this morning. Earlier this week, Adam Feuerstein of The Street attributed the recent strength in Arena shares to anticipation of a positive European approval recommendation today for its weight-loss pill Belviq. However, Belviq was not among the CHMP's decisions today.

View Comments (10)